<div id="readability-page-1"><p><span>Spruce Biosciences (NASDAQ:SPRB - Get Free Report)</span> was upgraded by Leerink Partnrs from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a note issued to investors on Wednesday,Zacks.com reports.</p><p>A number of other analysts have also recently issued reports on SPRB. Citigroup  restated a &#34;market perform&#34; rating on shares of Spruce Biosciences in a research note on Tuesday, November 11th. Wall Street Zen upgraded Spruce Biosciences to a &#34;sell&#34; rating in a research note on Saturday, November 15th. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Spruce Biosciences in a report on Monday. Leerink Partners raised Spruce Biosciences from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $160.00 price objective on the stock in a report on Wednesday. Finally, Citizens Jmp increased their price objective on Spruce Biosciences from $254.00 to $259.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Tuesday, November 11th. One analyst  has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat, the stock  has a consensus rating of &#34;Hold&#34; and a consensus price target of $178.88.</p><div><p><span></span><span>Get <strong>Spruce Biosciences</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Analysis on SPRB</b></p><h2>Spruce Biosciences Trading Up 1.1%</h2><p>NASDAQ SPRB opened at $90.16 on Wednesday. The firm has a market capitalization of $96.47 million, a P/E ratio of -1.06 and a beta of 3.45. The firm's fifty day moving average price is $108.33 and its two-hundred day moving average price is $42.17. Spruce Biosciences has a 1 year low of $4.28 and a 1 year high of $240.00. </p><p>Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($14.58) EPS for the quarter, topping the consensus estimate of ($15.56) by $0.98.  On average, research analysts anticipate that  Spruce Biosciences will post -1 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On Spruce Biosciences</h2><p>An institutional investor recently bought a new position in Spruce Biosciences stock. Carlyle Group Inc. purchased a new position in shares of  Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,896,518 shares of the company's stock, valued at approximately $24,765,000. Spruce Biosciences makes up   0.6% of Carlyle Group Inc.'s portfolio, making the stock its 4th largest position. Carlyle Group Inc. owned about 579.30% of Spruce Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own  91.71% of the company's stock. </p><h2>Spruce Biosciences Company Profile</h2> (Get Free Report)<p>Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Spruce Biosciences</li><li>What Are Treasury Bonds?</li><li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li><li>What Are Growth Stocks and Investing in Them </li><li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Spruce Biosciences Right Now?</h2><p>Before you consider Spruce Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spruce Biosciences wasn't on the list.</p><p>While Spruce Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SPRB

<p>Leerink Partners upgraded Spruce Biosciences (NASDAQ:SPRB) from a "hold" to a "strong-buy" rating. Other analysts have mixed ratings, with a consensus "hold" and a price target of $178.88. The stock opened at $90.16, with a market cap of $96.47 million. Carlyle Group Inc. recently acquired a significant stake in the company. Spruce Biosciences focuses on therapies for rare endocrine disorders, with its lead product in Phase 2b trials.</p>

Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs